20/20 Biolabs gets Nasdaq equity non-compliance notice; delisting risk

20/20 Biolabs, Inc.

• On Sept 3, 2026, Nasdaq notified 20/20 Biolabs of non-compliance with $2.5M stockholders' equity rule; reported equity $1.62M.
• Company has 45 days to submit compliance plan; if accepted, extension up to 180 days possible.
• Also previously notified July 17, 2026 of bid price non-compliance; must regain $1.00 bid by Jan 13, 2027.
• Failure to cure equity by Jan 13, 2027 would also disqualify additional bid-price cure period.
• Company intends to monitor and consider options to regain compliance.